|
注册号: Registration number: |
ChiCTR2400091713 |
|
最近更新日期: Date of Last Refreshed on: |
2024-11-01 15:12:40 |
|
注册时间: Date of Registration: |
2024-11-01 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
禾零舒缓保湿修护霜对非剥脱点阵激光术后修复的随机双盲半脸安慰剂对照研究 |
|
Public title: |
A randomized, double-blind, placebo-controlled study on He Ling cream for post-non-ablative fractional laser therapy |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
禾零舒缓保湿修护霜对非剥脱点阵激光术后修复的随机双盲半脸安慰剂对照研究 |
|
Scientific title: |
A randomized, double-blind, placebo-controlled study on He Ling cream for post-non-ablative fractional laser therapy |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
杨雨桐 |
研究负责人: |
王秀丽 |
|
Applicant: |
Yutong Yang |
Study leader: |
Xiuli Wang |
|
申请注册联系人电话: Applicant telephone: |
+86 177 1709 5517 |
研究负责人电话:
Study leader's |
+86 180 1733 6663 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
dryutong@163.com |
研究负责人电子邮件: Study leader's E-mail: |
125852634@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市静安区保德路1278号 |
研究负责人通讯地址: |
上海市静安区保德路1278号 |
|
Applicant address: |
No.1278 Baode Road, Jingan Disrtict, Shanghai, China |
Study leader's address: |
No.1278 Baode Road, Jingan Disrtict, Shanghai, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海市皮肤病医院 |
||
|
Applicant's institution: |
Shanghai Skin Disease Hospital |
||
|
研究负责人所在单位: |
上海市皮肤病医院 |
||
|
Affiliation of the Leader: |
Shanghai Skin Disease Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024-28(科) |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海市皮肤病医院临床试验伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Shanghai Skin Disease Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-08-22 00:00:00 | ||
|
伦理委员会联系人: |
刘硕 |
||
|
Contact Name of the ethic committee: |
Shuo Liu |
||
|
伦理委员会联系地址: |
上海市静安区保德路1278号 |
||
|
Contact Address of the ethic committee: |
No.1278 Baode Road, Jingan Disrtict, Shanghai, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 3680 3156 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
上海市皮肤病医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shanghai Skin Disease Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市静安区保德路1278号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.1278 Baode Road, Jingan Disrtict, Shanghai, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
海南康哲美丽科技有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Hainan Kangzhe Beauty Technology Co., Ltd. |
||||||||||||||||||||||
|
研究疾病: |
痤疮后凹陷性瘢痕 |
||||||||||||||||||||||
|
Target disease: |
Post-acne atrophic scars. |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
评价禾零舒缓保湿修护霜对非剥脱点阵激光术后修复的有效性和耐受性。 |
||||||||||||||||||||||
|
Objectives of Study: |
Evaluate the efficacy and tolerability of He Ling Cream for the repair after non-ablative fractional laser therapy. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1)孕期、哺乳期或随访期间准备怀孕者; 2)既往存在瘢痕疙瘩或增生性瘢痕者; 3)正在接受其它临床研究者; 4)面部存在影响疗效评价的其他皮肤疾病者; 5)1月内面部接受过光电治疗或外用促进表皮再生产品治疗者; 6)患有严重的系统性皮肤病、内科疾病、凝血功能障碍、心理及精神疾病、传染病者; 7)对外用产品的任何成分有已知的过敏或对利多卡因过敏者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1) Individuals who are pregnant, breastfeeding, or planning to become pregnant during the follow-up period; 2) Those with a history of keloids or hypertrophic scarring; 3) Participants who are currently involved in other clinical studies; 4) Individuals with other skin conditions on the face that may affect the evaluation of treatment efficacy; 5) Those who have received photoelectric therapy or topical products promoting epidermal regeneration on the face within the last month; 6) Patients with severe systemic skin diseases, internal diseases, coagulation disorders, psychological or psychiatric conditions, or infectious diseases; 7) Individuals with known allergies to any components of topical products or to lidocaine. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-11-01 00:00:00至 To 2025-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-11-01 00:00:00 至 To 2025-11-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由研究人员使用EXCEL软件生成随机数序列。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The researchers used EXCEL software to generate a sequence of random numbers. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
双盲 |
|
Blinding: |
Double blinded |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Not sharing |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
与伦理委员会相关的资料: 研究单位负责资料保存的人员必须保留伦理委员会会议记录及摘要,直至试验中止或完成后5年。如果申办者希望保留更长时间双方将讨论并决定保留时间和方法。如果试验单位对文件保存有任何改变负责资料保存的人员或研究者需要与申办者联系。 与试验实施相关的资料: 研究单位负责资料保存的人员必须保留以下资料,至研究结束后10年。如果申办者希望保留更长时间双方将讨论并决定保留时和方法。如果试验单位对文件保存有任何改变负责资料保存的人员或研究者需要与申办者联系。 (1)原始资料; (2)知情同意书的原件和其他由研究单位工作人员提供的与GCP相关的资料; (3)试验方案,从伦理委员会获得的GCP相关的资料或其他获得的GCP相关的资料; (4)试验中得到的数据。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Information related to the Ethics Committee: The personnel responsible for data preservation in the research unit must keep the minutes and abstracts of the ethics committee until the trial is discontinued or completed for 5 years. If the sponsor wishes to retain for a longer period of time, the parties will discuss and decide on the retention time and method. If there is any change in the document preservation by the experimental unit, the person or researcher responsible for data preservation needs to contact the sponsor. Information relevant to the conduct of the trial: The personnel responsible for data preservation in the research unit must retain the following data for 10 years after the end of the study. If the sponsor wishes to retain for a longer period of time, the parties will discuss and decide when and how to retain it. If there is any change in the document preservation by the experimental unit, the person or researcher responsible for data preservation needs to contact the sponsor. (1) Source materials; (2) Original informed consent form and other GCP-related information provided by the staff of the research unit; (3) Test protocol, GCP-related information obtained from ethics committees or other GCP-related information obtained; (4) Data obtained during the test. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |